Regeneron Reports Third Quarter 2026 Financial and Operating Results

REGENERON PHARMACEUTICALS, INC. (REGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Regeneron Reports Third Quarter 2026 Financial and Operating Results • Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025 • Dupixent ® global net sales (recorded by Sanofi) increased 35% to $6.5 billion • EYLEA HD ® U.S.

Event · Earnings
Also in this documentDividend · regular · $0.94Guidance · raise · $6.6B–$6.74B

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 30, 2026, 10:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 10:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$REGN
Bullish
high confidence
Mentioned
$REGN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$REGNBullishHigh
01

Why it matters

The earnings beat and cash payment are likely to drive short‑term buying interest, while pipeline progress may sustain longer‑term upside.

02

Market read

First‑report earnings for a large‑cap biotech with strong growth and a sizable partnership cash infusion.

03

What to watch

Potential regulatory risk for upcoming approvals and the need for continued pipeline success.

Relevance 8/10Novelty 8/10Timing: today
AlphAI · Earnings readREGN · Q3 2026 · ended September 30, 2026

Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025; GAAP EPS increased 35% to $18.45 and non-GAAP EPS increased 70% to $20.07.

✓Strong quarter

Total revenues grew 36%, led by a 68% increase in Sanofi collaboration revenue, while GAAP diluted EPS rose 35% and non-GAAP diluted EPS rose 70%. EYLEA HD U.S. sales, global Libtayo sales, and Dupixent global sales all grew, although EYLEA U.S. sales declined 41%.

Revenue
$5.12B
36 % y/y
EYLEA HD - U.S.
$699M
62 % y/y
Gross margin · GAAP
82%
EPS · non-GAAP
$ 20.07
70 % y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 total revenuesGAAP$5.12B–36 %
Q3 2026 net product salesGAAP$1.81B–14 %
Q3 2026 collaboration revenueGAAP$3.00B––
Q3 2026 other revenueGAAP$310M–57 %
Q3 2026 income from operationsGAAP$2.05B––
Q3 2026 net incomeGAAP$1.95B–33 %
Q3 2026 net income per share - basicGAAP$ 19.16––
Q3 2026 net income per share - dilutedGAAP$ 18.45–35 %
Q3 2026 non-GAAP net incomenon-GAAP$2.15B–67 %
Q3 2026 non-GAAP net income per share - basicnon-GAAP$ 21.14––
Q3 2026 non-GAAP net income per share - dilutednon-GAAP$ 20.07–70 %
Q3 2026 research and developmentGAAP$1.79B–22 %
Q3 2026 research and developmentnon-GAAP$1.65B–23 %
Q3 2026 acquired in-process research and developmentGAAP$21.5M–(73 %)
Q3 2026 selling, general, and administrativeGAAP$677.8M–3 %
Q3 2026 selling, general, and administrativenon-GAAP$588.3M–9 %
Q3 2026 cost of goods soldGAAP$321.7M–15 %
Q3 2026 cost of goods soldnon-GAAP$245.7M–8 %
Q3 2026 gross margin on net product salesGAAP82%––
Q3 2026 gross margin on net product salesnon-GAAP86%––
Q3 2026 cost of collaboration and contract manufacturingGAAP$251.9M–5 %
Q3 2026 effective tax rateGAAP14.7%––
Q3 2026 effective tax ratenon-GAAP15.0%––
Nine months ended September 30, 2026 total revenuesGAAP$13.01B––
Nine months ended September 30, 2026 net incomeGAAP$3.97B––
Nine months ended September 30, 2026 net income per share - dilutedGAAP$ 37.37––
Nine months ended September 30, 2026 non-GAAP net incomenon-GAAP$4.73B––
Nine months ended September 30, 2026 non-GAAP net income per share - dilutednon-GAAP$ 43.70––
Nine months ended September 30, 2026 gross margin on net product salesGAAP79%––
Nine months ended September 30, 2026 gross margin on net product salesnon-GAAP86%––
Nine months ended September 30, 2026 net cash provided by operating activitiesGAAP$3.68B––
Nine months ended September 30, 2026 capital expendituresother$771M––
Nine months ended September 30, 2026 free cash flownon-GAAP$2.90B––

Segments

SegmentRevenueq/qy/y
EYLEA HD - U.S.Higher sales volumes driven by increased demand, partly offset by a lower net selling price.$699M–62 %
EYLEA - U.S.Lower sales volumes resulting from continued competitive pressures and the continued transition of patients to EYLEA HD.$400M–(41 %)
Total EYLEA HD and EYLEA - U.S.EYLEA HD growth was offset by lower EYLEA sales.$1.10B–(1 %)
Libtayo - U.S.Higher sales volumes driven by increased demand.$396M–81 %
Libtayo - ROWNo driver quantified in the release.$154M–5 %
Total Libtayo - GlobalU.S. net product sales increased primarily due to higher sales volumes driven by increased demand.$550M–51 %
Praluent - U.S.No driver quantified in the release.$ 81–21 %
Evkeeza - U.S.No driver quantified in the release.$ 55–28 %
Lynozyfic - GlobalPercentage was not meaningful or greater than 100%.$ 19––
Other products - GlobalPercentage was not meaningful or greater than 100%.$ 1––
Sanofi collaboration revenueHigher share of profits from commercialization of antibodies, primarily associated with higher Dupixent sales, and the Sanofi Development Balance no longer reduced collaboration revenue.$2.72B–68 %
Bayer collaboration revenueNo driver quantified in the release.$267M–(23 %)
Other collaboration revenueNo driver quantified in the release.$ 10–67 %
Dupixent global net sales, recorded by SanofiHigher Dupixent sales contributed to higher Sanofi collaboration revenue.$6.54B–35 %
EYLEA HD global net salesU.S. demand-driven volume growth was partly offset by a lower net selling price.$1.08B–63 %
EYLEA global net salesContinued competitive pressures and the transition of patients to EYLEA HD.$658.4M–(49 %)
Kevzara global net sales, recorded by SanofiNo driver quantified in the release.$255.6M–66 %

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

Full year 2026 outlook

  • Gross marginGAAP gross margin on net product sales: 78%–79%; non-GAAP gross margin on net product sales: 84%–85%
  • Operating expensesGAAP R&D: $6.500–$6.635 billion; non-GAAP R&D: $5.950–$6.050 billion; GAAP SG&A: $2.830–$2.960 billion; non-GAAP SG&A: $2.500–$2.600 billion; GAAP COCM: $985 million–$1.035 billion; non-GAAP COCM: $970 million–$1.020 billion
  • Tax rateGAAP effective tax rate: 13%–14%; non-GAAP effective tax rate: 14%–15%
  • NoteCapital expenditures: $1.030–$1.100 billion
  • NoteThe Company's 2026 financial guidance does not assume the completion of any business development transactions not completed as of the date of this press release.

Capital returns

  • During the nine months ended September 30, 2026, the Company repurchased $2.3 billion of its common stock.
  • As of September 30, 2026, $2.2 billion remained available for share repurchases under the Company's share repurchase programs.
  • In October 2026, the Company declared a cash dividend of $0.94 per share on the Company's common stock and Class A stock, payable on December 3, 2026 to shareholders of record as of November 20, 2026.

What drove it

  • Sanofi collaboration revenue rose as the Company's share of profits from commercialization of antibodies increased to $2.575 billion from $1.456 billion, primarily associated with higher Dupixent sales.
  • The Sanofi Development Balance was fully repaid as of the end of the second quarter of 2026 and no longer reduced Sanofi collaboration revenue beginning in the third quarter of 2026.
  • GAAP and non-GAAP R&D increased due to clinical pipeline advancement and increased manufacturing activity associated with product candidates.
  • The Company received an up-front payment of $1.0 billion under its expanded Sanofi antibody collaboration, to be recognized as collaboration revenue in the fourth quarter of 2026.
  • Pasatru was approved by the FDA in August 2026 for adults with FOP.

Concerns

  • EYLEA U.S. net product sales decreased due to continued competitive pressures and continued patient transition to EYLEA HD.
  • Bayer collaboration revenue decreased 23%.
  • GAAP gross margin on net product sales for the nine months ended September 30, 2026 was 79%, compared to 82% in the prior-year period; the reconciliation identified temporary manufacturing interruption-related costs of 3%.
  • GAAP other income (expense), net decreased primarily due to lower net gains on marketable and other securities.

What to watch

  • FDA target action date for cemdisiran in generalized myasthenia gravis is expected next month.
  • The FDA target action date for Ordspono in relapsed or refractory diffuse large B-cell lymphoma is February 2027.
  • The FDA target action date for the Libtayo alternative dosing schedule sBLA is March 2027.
  • The Company plans to initiate a Phase 3 study in MASH/MASLD in the fourth quarter of 2026.
  • The Company plans to report Phase 2 baloncibart results in POTS in November 2026 and plans to initiate a Phase 3 study in the first half of 2027, pending regulatory feedback.
  • The $1.0 billion Sanofi up-front payment is expected to be recognized as collaboration revenue in the fourth quarter of 2026.

Balance sheet and cash flow

  • Cash and marketable securities as of September 30, 2026: $ 18,858.5; December 31, 2025: $ 18,865.8.
  • Long-term debt as of September 30, 2026: $ 1,987.0; December 31, 2025: $ 1,985.9.
  • Accounts receivable, net as of September 30, 2026: $ 7,578.6; December 31, 2025: $ 5,741.1.
  • Inventories as of September 30, 2026: $ 2,894.6; December 31, 2025: $ 3,200.8.
  • Nine months ended September 30, 2026 net cash provided by operating activities: $ 3,675.3; capital expenditures: $ 771.0; free cash flow: $ 2,904.3.

Analysis

Regeneron reported a strong third quarter, with total revenues of $ 5,115.8 versus $ 3,754.3 in the third quarter of 2025. Collaboration revenue of $ 3,000.5 was the largest revenue stream and included $ 2,724.0 from Sanofi. Sanofi collaboration revenue benefited from higher profit sharing on antibody commercialization, primarily linked to higher Dupixent sales, and from the end of Sanofi Development Balance reductions beginning in the third quarter. Net product sales increased to $ 1,805.3 from $ 1,587.7.

Commercial performance reflected continued portfolio mix changes. EYLEA HD U.S. sales rose 62% to $ 699, supported by demand-driven volume gains, while EYLEA U.S. sales fell 41% to $ 400 amid competitive pressures and patient transitions to EYLEA HD. Combined U.S. EYLEA HD and EYLEA sales were $ 1,099, down 1%. Libtayo global sales increased 51% to $ 550, including 81% growth in U.S. sales to $ 396. Dupixent global net sales recorded by Sanofi increased 35% to $ 6,540.5.

Profitability expanded despite higher development spending. GAAP net income was $ 1,948.7 and non-GAAP net income was $ 2,150.0. GAAP diluted EPS was $ 18.45, while non-GAAP diluted EPS was $ 20.07. GAAP R&D increased to $ 1,794.7 and non-GAAP R&D increased to $ 1,653.8, with the release citing pipeline advancement and increased manufacturing activity. Third-quarter GAAP and non-GAAP gross margin on net product sales were unchanged at 82% and 86%, respectively.

Capital deployment included $2.3 billion of common-stock repurchases during the nine months ended September 30, 2026, with $2.2 billion remaining authorized at period end. The company declared a $0.94 per-share cash dividend in October. Cash and marketable securities were $ 18,858.5 and long-term debt was $ 1,987.0 as of September 30, 2026. Nine-month free cash flow was $ 2,904.3.

Full-year 2026 guidance calls for GAAP R&D of $6.500–$6.635 billion, non-GAAP R&D of $5.950–$6.050 billion, GAAP gross margin on net product sales of 78%–79%, and non-GAAP gross margin of 84%–85%. The company also expects capital expenditures of $1.030–$1.100 billion. The expanded Sanofi agreement produced a $1.0 billion up-front payment expected to be recognized as collaboration revenue in the fourth quarter of 2026, with potential additional milestones of up to $7.0 billion.

Management, verbatim

This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales.

Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron

Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever.

Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported Q3 operating metrics were not provided.
  • Quarterly operating cash flow and quarterly free cash flow were not provided.
  • A full-year 2026 revenue guidance figure was not provided.
  • Quarterly dividend cash amount and dividend payment history were not provided.
  • Total debt beyond the reported long-term debt line was not provided.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Regeneron filed a Form 8‑K reporting its third‑quarter 2026 financial and operating results, including product sales, pipeline updates, and a new Sanofi collaboration.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Regeneron disclosed Q3 2026 results with 36% revenue growth to $5.1B and 35% GAAP EPS increase to $18.45, plus a $1B upfront Sanofi collaboration payment.

Expected impact

likely upward pressure as the market prices in the revenue and EPS beat and the new collaboration cash.

Evidence & confidence

The disclosed growth rates and cash infusion are material for a large‑cap biotech, suggesting investors will bid the stock higher on the news.

Market effects

Boosts biotech sector sentiment, especially peers with immunology pipelines.

Positive for US biotech listings on Nasdaq.

Highlights Sanofi partnership benefits, may influence European biotech valuations.

Counterpoint

If the market had already priced in strong growth, the reaction could be muted.

Key entities

  • Regeneron Pharmaceuticals, Inc.

    US‑listed biotech company reporting Q3 2026 results.

  • Sanofi

    Partner in a collaboration delivering $1B upfront and up to $7B in milestones.

Every REGN earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$REGNMed

These patients struggle with runaway bones. Finally there’s hope

The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.